7-Dehydrocholesterol (7-DHC) is a common precursor of
vitamin D3 and
cholesterol. Although various
oxysterols, oxygenated
cholesterol derivatives, have been implicated in cellular signaling pathways,
7-DHC metabolism and potential functions of its metabolites remain poorly understood. We examined
7-DHC metabolism by various
P450 enzymes and detected three metabolites produced by
sterol 27-hydroxylase (CYP27A1) using high-performance liquid chromatography. Two were further identified as
25-hydroxy-7-DHC and 26/27-hydroxy-7-DHC. These
7-DHC metabolites were detected in serum of a patient with
Smith-Lemli-Opitz syndrome.
Luciferase reporter assays showed that
25-hydroxy-7-DHC activates
liver X receptor (LXR) α, LXRβ and
vitamin D receptor and that 26/27-hydroxy-7-DHC induces activation of LXRα and LXRβ, although the activities of both compounds on LXRs were weak. In a mammalian two-hybrid assay,
25-hydroxy-7-DHC and 26/27-hydroxy-7-DHC induced interaction between LXRα and a coactivator fragment less efficiently than a natural LXR agonist,
22(R)-hydroxycholesterol. These
7-DHC metabolites did not oppose agonist-induced LXR activation and interacted directly to LXRα in a manner distinct from a potent agonist. These findings indicate that the
7-DHC metabolites are partial LXR activators. Interestingly,
25-hydroxy-7-DHC and 26/27-hydroxy-7-DHC suppressed
mRNA expression of
sterol regulatory element-binding protein 1c, an LXR target gene, in HepG2 cells and HaCaT cells, while they weakly increased
mRNA levels of
ATP-binding cassette transporter A1, another LXR target, in HaCaT cells. Thus,
7-DHC is catabolized by CYP27A1 to metabolites that act as selective LXR modulators.